The United Kingdom and the United States have announced a landmark trade agreement that will ensure zero import taxes on British medicine exports entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the public health system. This move guarantees that tariffs on these crucial goods will stay at nothing for a timeframe of three years.
This deal is in response to previous warnings to significantly raise import taxes on patented drug imports, with figures floated up to one hundred percent.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and introduces long-overdue balance to U.S.–U.K. drug exports," a statement declared.
Commercial Importance
Medicines are one of the the United Kingdom's biggest exports to the US, which is clearly the primary destination for major British pharmaceutical firms.
Statistics show that in the year prior to September, the UK exported medicines totaling billions to the US. This amount accounted for a significant portion of all goods exports in that period.
"This agreement protects work, increases funding and paves the way for the UK to emerge as a global hub for life sciences," the Business and Trade Secretary remarked.
Key UK Commitments
The deal entails several key pledges from the United Kingdom:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The sum drug companies must pay back to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments were more than 20%.
Recent Tensions
The deal follows a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and NHS adoption.
The disagreement were exacerbated by arguments that US consumers were paying several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several significant drug company projects in the UK have been delayed or scrapped, while substantial expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its spending on drugs had decreased as a proportion of its resources over the previous ten-year period.
